Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-26 DOI:10.2217/pme-2021-0047

Mehtap Cevik, Esat Namal, Nur Dinc Sener, Ulkuhan Iner Koksal, Penbe Cagatay, Gokce Deliorman, Cavlan Ciftci, Atila Karaalp, Belgin Susleyici

{"title":"Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer.","authors":"Mehtap Cevik, Esat Namal, Nur Dinc Sener, Ulkuhan Iner Koksal, Penbe Cagatay, Gokce Deliorman, Cavlan Ciftci, Atila Karaalp, Belgin Susleyici","doi":"10.2217/pme-2021-0047","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the association of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. Materials & methods: A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several DPYD, MTHFR and TYMS polymorphisms using a microarray analyzer. Results: DPYD 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0-2, but not severe toxicities (p = 0.02). Furthermore, patients with DPYD 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60; p = 0.01 and log rank = 4.40; p = 0.04, respectively). Conclusion: According to our results, DPYD 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another DPYD polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"435-444"},"PeriodicalIF":1.7000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0047","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the association of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. Materials & methods: A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several DPYD, MTHFR and TYMS polymorphisms using a microarray analyzer. Results: DPYD 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0-2, but not severe toxicities (p = 0.02). Furthermore, patients with DPYD 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60; p = 0.01 and log rank = 4.40; p = 0.04, respectively). Conclusion: According to our results, DPYD 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another DPYD polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results.

查看原文本刊更多论文

DPYD、MTHFR和TYMS多态性对结直肠癌5-氟尿嘧啶相关毒性的影响

目的:探讨DPYD、MTHFR和TYMS多态性与5-氟尿嘧啶(5-FU)相关毒性及患者生存的关系。材料与方法:本研究共纳入103例使用5-FU的结直肠癌患者。使用微阵列分析仪对几种DPYD、MTHFR和TYMS多态性进行基因分型。结果:DPYD 496A>G多态性与5-FU相关的0-2级显著相关，但与严重毒性无关(p = 0.02)。此外，在我们的研究组中，与TT基因型相比，DPYD 85TC和CC基因型患者的进展时间和总生存时间更长(log rank = 6.60;P = 0.01, log rank = 4.40;P = 0.04)。结论:与AA基因型相比，DPYD 496AG和GG基因型可能对严重不良事件具有保护作用。另一种DPYD多态性85T>C可能与结直肠癌预后有关。这两种多态性的进一步研究应在更大的人群中进行，以获得准确的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.